Thermo Fisher reported flat Q1 revenue of $10.36 billion, beat profit estimates, and navigates tariff challenges.

From Barchart: 2025-04-23 17:33:00

Thermo Fisher (NYSE:TMO) reported Q1 CY2025 revenue of $10.36 billion, beating analyst estimates, but flat year on year. Non-GAAP profit was $5.15 per share, exceeding estimates by 0.9%. The stock remained flat at $433.50 post-earnings. Key insights include stable demand in bioproduction and pharma services, challenges from new tariffs and evolving U.S. policy, and ongoing innovation and strategic investments. Analyst questions focused on tariff mitigation, demand trends, pricing actions, and growth prospects. Looking ahead, Thermo Fisher aims to offset external pressures through operational flexibility and investment in U.S. manufacturing and R&D.

Thermo Fisher’s Q1 results featured revenue of $10.36 billion, adjusted EPS of $5.15, and adjusted EBITDA of $2.55 billion. Performance was driven by bioproduction and pharma services, while academic and government revenue declined due to funding cuts. The company is navigating tariff-related headwinds and policy changes through supply chain adjustments and selective pricing actions. Analysts will monitor progress on these fronts, the Soventum acquisition, and demand stabilization. Find out if TMO is a buy or sell post-earnings in a free research report. Explore our curated list of Top 9 Market-Beating Stocks for long-term gains.



Read more at Barchart: Navigating Tariffs and Macro Uncertainty While Investing in Innovation